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1) Introduction 
In this Appendix we utilise the Mini-Mental State Examination (MMSE) score of patients with Alzheimer’s 
Disease to establish a relationship between disease progression and quality of life measures and we also 
compare our results to findings from the literature review about Alzheimer’s patients utility. 
2) Use of Existing Quality of Life evidence from the ADENA trials to estimate the utility impact of Exelon® 
The purpose of the work reported in this first part of the Appendix is to map the outcome measures used on the 
ADENA Exelon® (rivastigmine) drug trials onto the Health Utilities Index (HUI III Furley et al 1998) utility 
index in order to create a Quality of Life measure that can be used in a cost- effectiveness analyses of the drug. 
The mapping process uses the questionnaires involved in eliciting ADAS- Cog, PDS and CIBIC+ scales and, 
by a comparison of the questions and multiple- choice answers in those questionnaires with those in the HUI III 
questionnaire, allows a utility index to be constructed. 
 The HUI III utility index was chosen, rather than another utility index because it includes Cognition as a 
dimension on the multi- attribute scale. This makes the assessment of utility scales far simpler because of the 
large cognitive element in Alzheimer’s Disease. The outcome measures used in the ADENA trials therefore 
would be particularly appropriate for such mapping. This does not occur on other utility indices, while HUI II is 
not as tightly defined as HUI III. Furthermore HUI III has the advantage of having its weights based on the 
standard gamble (Neumann 1998) 
 The HUI III utility index is a general utility scale for health states that has a wide range of application across 
all types of disease. (Feeny et al. 1996) It is not tailored specifically to Alzheimer’s Disease (AD) so that not all 
the dimensions used in assessing illness will be suitable for describing its symptoms. However, by contrast, the 
outcome measures used in the ADENA trials are well  suited for describing and measuring the symptoms of 
AD. When mapping between the outcome measures and the utility scale, one needs to decide which parts of the 
utility scale are relevant to AD. In the case of the HUI III index the Speech, Cognition, Ambulation and 
Emotion dimensions were deemed relevant, while the Hearing, Vision, Dexterity and Pain dimensions were 
deemed irrelevant to the condition of AD. 
 Although the latter four dimensions were deemed irrelevant to AD they could not be ignored. HUI III is a 
multi- attribute utility index, composed of several dimensions that need to be combined together. The function 
used to combine the dimensions together is multiplicative. This means that the dimensions are not independent 
of each other, so that some realistic value must be found for each of the irrelevant dimensions. The method used 
was to put in a value obtained from the average value for each dimension derived from previous work (c.f. 
Neumann 1999). For each dimension, this average value was rounded  to the nearest utility number, 
corresponding to a health state on that dimension. 
 The remaining four dimensions were mapped onto the three outcome measures as follows. Speech and 
Cognition were mapped from ADAS- Cog; Ambulation was mapped from the PDS and Emotion was mapped 
from the CIBIC+ (Novartis 1997 for source of questionnaires etc.). Not all the mappings were simple and all 
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required certain assumptions to be made in order for the mapping to be valid. Even the simplest required a 
certain amount of interpretation of the item responses to make them fit. One aspect of this, for example, was the 
setting of the questionnaires. HUI III is very general and is meant to refer to the patient’s whole life at that 
point in time. By contrast, the three outcome measures refer to the clinician’s impression of the patient in the 
surgery. An assumption had to be made therefore that this impression applied outside the surgery.  
 The first dimension to be mapped was that of speech, which was mapped onto “Spoken Language Ability” in 
ADAS- Cog. The latter is a six point scale which goes from 0, “no instance where it is difficult to understand 
the patient” to 5, “severe”. The mapping here was quite simple since the two end-points correspond across 
scales quite well and the second to fourth scores in ADAS- cog are similar to the second to fourth scores on 
HUI III. The only manipulation was that point 1 on ADAS-cog, “very mild”, was also counted as 1 on HUI III, 
as well as point 0.  
Table 3. 3. 1 Mapping of Speech items 
ADAS-Cog -Speech HUI III - Speech 
0,1 1 
2 2 
3 3 
4 4 
5 5 
 The second dimension to be mapped was that of Cognition. This was by far the most complex of the four 
dimensions, in that no less than five items from ADAS- Cog had to be mapped onto the HUI III cognition 
dimension. Furthermore, the Cognition dimension is not directly derived from the HUI III questionnaire but 
from two “sub- dimensions”; Thinking and Memory, which are then combined. Of the five items mapped onto 
cognition, three were mapped onto memory and two onto thinking. 
  The three items from ADAS- cog mapped onto the Memory sub- dimension were Word Recall, Word 
Recognition (which involved a memory task) and Remember Instructions. First of all each individual item was 
mapped onto Memory. In the case of Word Recall and Word Recognition this created a problem because, in 
both cases, the scales were not discrete. This meant that the memory scale (a four point scale) had to be mapped 
to intervals in the word recall scale that varied from a low of 0 to a maximum of 10. Similarly, the memory 
scale mapped to intervals in the word recognition item. Remember Instructions, by contrast, was a discrete six- 
point scale that had to be mapped to the four- point scale of Memory. 
Table 3. 3. 2 Mapping of items onto Memory 
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Word Recall Word Recognition Remember Instructions 
HUI III ADAS- Cog HUI III ADAS -Cog HUI III ADAS- cog 
0-2.5 1 0-2.5 1 1 0 
0.25-4.5 2 2.5-5.5 2 2 1,2 
4.5- 9.5 3 5.5-11.5 3 3 3,4 
9.5- 10 4 11.5-12 4 4 4 
 For the Thinking sub- dimension of  the Cognition dimension, the two items mapped from ADAS- Cog were 
Comprehension and Ideational Praxis. The former evaluated the patient’s ability to understand speech, while 
the latter evaluated the patient's ability to follow complex instructions. Both were discrete, so there were no 
problems with continuity. Ideational Praxis was relatively simple to map, with the two endpoints similar. 
However, Comprehension was more problematic in that the lower endpoints did not match. In particular, it was 
not thought that “severe” in Comprehension matched “unable to think or solve any problems” which suggested 
a far worse problem. This meant that the lowest point in Comprehension only mapped onto the second lowest 
point on Thinking.  
Table 3. 3. 3 Mapping of items onto thinking   
Ideational Praxis Comprehension 
HUI III ADAS- Cog HUI III ADAS- Cog 
1 0 1 0,1 
2 1 2 2 
3 2,3 3 3 
4 4 4 4,5 
5 5 5 *** 
 Having mapped the individual items in ADAS- cog onto the Thinking and Memory sub- dimensions on HUI 
III, it was necessary to combine the mappings together to produce scores for the sub- dimensions. This was 
done, in each case, by taking a mean of the  mappings and rounding to the nearest whole number. This gave the 
mapped Thinking and Memory sub- dimensions. 
 Getting from the sub- dimensions to the Cognition dimension was a complex process in itself. In HUI III  the 
Cognition dimension is formed by assigning numbers to descriptions formed from combinations of the thinking 
and memory sub- dimension answers (Furlong et al. 1998). However, out of a possible twenty combinations  of 
sentences possible by combining  the Thinking and Memory sub- dimensions together, only six have been 
labelled with a number in the cognition dimension. Unfortunately the six labelled do not cover all the 
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combinations which exist in the data. The solution to this problem was to make   assumptions about which of 
these combinations could be counted as belonging to which number. 
Table 3. 3. 4 Combining Memory and Thinking into Cognition 
 THINKING 
  1 2 3 4 5 
 1 i ii iv v vi 
MEMORY 2 iii iv iv v vi 
 3 v v v v vi 
 4 vi vi vi vi vi 
 
 In the table above, the roman numerals give the ranking on the cognition scale of combinations of the memory 
and thinking sub- scales. The numerals in bold are those recommended in the HUI III questionnaire. The 
numerals in italics were decided by the assumption that if the cell shared a point on either of the subscales with 
one of the bold numerals, which was the lowest possible, then it would have the same point on the cognitive 
scale as that numeral. 
 The third relevant dimension on HUI III was that of Ambulation. This was mapped onto Walking Ability on 
the PDS scale. This presented three problems, one technical and two with interpretation. The latter is related to 
the fact that the link between the two scales is only partial. The ambulation scale is concerned with the ability 
to walk safely, but is also concerned by the need for walking aids. By contrast, the walking ability scale, while 
also being concerned with walking safety, is in addition concerned with the patient’s propensity to become lost. 
The mapping between the two is therefore a partial mapping between the ability to walk safely on both scales. 
One result of this partial relationship is that the lowest points on the scale do not match. On HUI III this is 
“Cannot walk at all” whereas the PDS merely describes the patient as being “unsafe” to leave the house. It was 
decided that the latter corresponded better with point 5 on the Ambulation Scale.    
 The technical problem was that the PDS scale is measured on a Visual Analogue Scale rather than on a discrete 
scale such as the ADAS- cog measure. This was solved by assuming that the scale was equally split up between 
the points used on the Ambulation scale. Point 1 on the ambulation scale, for example, was assumed to match 
up with 100 to >80 on the walking ability scale. Point 5 by contrast corresponded to a range of 0 to 20.  
Table 3. 3. 5 Mapping onto Ambulation 
PDS- Walking Ability HUI III -AMBULATION 
>80 1 
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60-80 2 
40-60 3 
20-40 4 
0-20 5 
 
 The fourth relevant dimension on the HUI III scale is that of Emotion, which principally measures the amount 
of depression experienced by patients. This was fairly easily mapped onto the depression subscale of the 
patient’s interview (attitude/behavioural section)  on the CIBIC+ measure. The depression subscale goes from 0 
(not present) to 3 (Present with emotional and physical concomitants. The HUI III index goes from 1 to 5. 
However 5 on the scale (So unhappy that life is not worthwhile) seemed substantially worse than 3 on the 
CIBIC+ scale, so 4 is mapped onto 3 instead. The mapping is shown in the table below: 
Table 3. 3. 6 Mapping onto Emotion 
     CIBIC+- Depression HUI III- Emotion 
0 1,2 
1 3 
2,3 4 
 Each dimension was then allocated a pre- determined utility score depending on where the dimension was 
mapped on the questionnaire.  Given the four relevant dimensions and the four irrelevant dimensions in the 
HUI III scale, it was possible to construct a full utility index using a multiplicative function to combine the 
utility elements together. The formula used was: 
               u = 1- (1/c)(j (1+c * cj * (1-uj))-1 )   
where u is the total utility, uj is the utility for an dimension in the utility function, cj is the constant for each 
dimension and c is a universal constant. The constants had been estimated from previous work (see Furlong et 
al. 1998). 
 Once this was done then the averages of the utility scores between baseline and 26 weeks was calculated for 
both Exelon and placebo treatments. The utility scores for intermediate points were ignored because these 
points did not appear consistently in the data. Instead it is assumed that the change in utility between the two 
points is linear. The averages were then used to calculate the gain/ loss in utility over time. The tables below 
give the utility averages for placebo and rivastigmine patients at baseline and 26 weeks. They also give the 
differences between baseline and 26 weeks, representing the improvement or decline of the patients in that 
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time. Also calculated is the difference between the differences- or how much of an improvement rivastigmine is 
over placebo. The two tables are for all doses and for high dose only. 
Table 3. 3. 7 Mean Utility Results from Pooled Trials (303 and 352) – All doses 
 Baseline 26 Week Difference 95% Confidence 
Interval 
Placebo 0.703425 0.678378 0.025047 +0001379 
Exelon® 0.682718 0.690545 -0.00783 +0.005315 
  Difference 0.032875  
 
Table 3. 3. 8 Utility Results from Pooled Trials (303 and 352) -High Dose Rivastigmine Only 
 Baseline 26 Week Difference 95% Confidence 
Interval 
Placebo 0.703425 0.678378 0.025047 +0.001379 
Exelon® 0.670813 0.702671 -0.03186 +0.000931 
  Difference 0.056906  
 As can be seen from the tables above, in the first table the improvement as a result of using rivastigmine is less 
than that assured in the Wessex DEC report (1998), whereas in the second table the numbers are higher. This is 
in line with what would be expected from the overall results where only the high- dose rivastigmine has a 
significant effect on the progress of the disease.  
 In order to test for the robustness of this mapping, a similar process of averaging the scores for each individual 
item on the ADAS- cog, CIBIC+ and PDS scales was used. This averaged over all the cases representing 
baseline and 26 weeks for each item used in these measures. The differences in performance on each of these 
scales were calculated. The results were then normalised so that the item averages varied between 0 and 1 to 
allow comparison with the utility scores. In absolute terms, the magnitude of the score changes varied between 
0.06823 (remember instructions) and 0.002964 (Emotion). These scores are within the range expected, given 
the high dose utility difference in performance (0.056906) and the all- dose utility difference in performance 
(0.032875).  
After having constructed utility scores for each patients the utility scores and their corresponding  MMSE 
scores were put into a regression model. 
3) Summary of ADENA evidence 
The figure below shows the relationship of utility to MMSE score on the two ADENA trials (303 and 352) 
population. Patients’ baseline and 26-week data were used.   
Figure 3. 3. 1. Utility against MMSE score for patients in the ADENA trials 
 
 
A trend of higher utility related to higher MMSE status can be seen and statistical regression confirmed the 
slope and significance of the relationships. 
Table 3. 3. 9. Result of the statistical regression of individuals’ MMSE scores versus utility 
Variable B 95% Confidence Interval for B t-value Significance 
Constant 0.0982 0.0735 0.1228 7.8130 0.0000
MMSE 
score 0.0298 0.0286 0.0310 48.4330 0.0000
   
Regression 
type 
Dependent 
Variable  R Square 
Adjusted R 
Square F Change 
Significance of F 
Change 
linear UTILITY 0.5185 0.5183 2345.7948 0.0000
 
The conclusion is that a reduction in MMSE of 1 point is roughly equivalent to a reduction in utility of 0.03.   
These results match reasonably well with the quality of life results shown in Table A 3.3.7 and Table A 3.3.8 
Figure A 3.3.2 below shows the mean utility for each MMSE score from the base line and the 26 week data.  It 
can be clearly seen that the reductions in MMSE correspond well with reductions in utility.  
Figure 3. 3. 2 Relationship between utility and MMSE scores in the ADENA trials 
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Number of 
observations 7 21 26 50 153 166 165 173 178 138 161 135 145 104 107 91 78 65 64 57 48 12 15 6 9 2
MMSE 
SCORE 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5
Mean utilty 
score 0.93 0.93 0.88 0.89 0.87 0.86 0.80 0.79 0.76 0.72 0.71 0.67 0.64 0.62 0.58 0.54 0.52 0.49 0.42 0.40 0.38 0.38 0.35 0.26 0.36 0.21
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At 6 months rivastigmine clearly gives a quality of life benefit. The quality of life benefit is proportional to the 
delay in MMSE reductions.   
4) Literature Evidence on Quality of Life with patients with Alzheimer’s disease 
There is very little literature on the relationship between dementia and QALYs.  However there is a short 
chapter by Peter Neumann, Richard Herman, and Milton Veinstein entitled “Measuring QALYs in Dementia” 
which is contained within the book Health Economics of Dementia (edited by Anders Wimo, Bengt Jonsson, 
Goran Karlsson and Bengt Winblad). The researchers review the various different methodological issues in 
relation to developing QALYs.  
The authors then move on to undertake an analysis of Quality of Life data which used “A companion, cross 
sectional study of 528 care givers of Alzheimer’s Disease patients, stratified by disease stage (mild, moderate, 
and severe based on the clinical dementia rating staging), and setting of care (community and nursing home) to 
obtain the utility weights.  The 528 patients included 201 mild, 175 moderate and142 severe; of these 354 were 
cared for in community settings and 164 in nursing homes.“ 
“In the cross sectional study, the study investigators administered the health utilities index mark 2.  This was 
chosen because it provides a means of obtaining community based preference rates in accordance with the US 
panel on cost effectiveness recommendations for reference case analyses and because weights are based on the 
standard gamble method.  Another advantage of the HUI 2 is that, unlike other preference weighted health 
status classification systems, the HUI 2 contains cognition as a separate attribute which may make it more 
sensitive to changes in Alzheimer’s Disease stage.  The HUI 2 questionnaire was completed by primary care 
givers as proxy respondents.  The responses were converted into preference weights using the HUI 2  multi-
attribute utility function (Torrance et al, 1995).” 
Table A 3.3.11. shows the weights obtained from the cross sectional study.  
Table 3. 3. 10. Estimates of quality-of-life weights across Alzheimer’s disease stages and settings of care 
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Stage/Setting Quality-of-Life Weights 
 Patients Caregivers 
Mild AD 
   Community 
   Nursing Home 
 
0.68 
0.71 
 
0.86 
0.86 
Moderate AD 
   Community 
   Nursing Home 
 
0.54 
0.48 
 
0.86 
0.88 
Severe AD 
   Community 
   Nursing Home 
 
0.37 
0.31 
 
0.86 
0.88 
Source: Neumann et al (1998) Table 3.4.5 
In another cross sectional study Neumann et al (1999) assessed the utility scores of 679 Alzheimer’s disease 
patient/caregiver pairs in different disease stages. Patients’ AD stage was determined by clinicians using 
Clinical Dementia Rating (CDR) scale, which closely corresponds to MMSE. They classified AD into one of 
six categories. HUI 2 scores were converted into global utility score with using the multi- attributable utility 
function. See results of the Neumann et al (1999) study. 
Table 3. 3. 11 Patients HUI score by CDR severity level and service setting 
AD severity Patients Caregivers 
Questionable 
(CDR=0.5) 
0.73 0.88
Mild (CDR=1) 0.69 0.87
Moderate (CDR=2) 0.53 0.87
Severe (CDR=3) 0.38 0.86
Profound (CDR = 4) 0.27 0.9
Terminal (CDR = 5) 0.14 0.93
Source: Neumann et al (1999) Table 3.4.6 
Leon et al (2000) analysed the same patient population but put more emphasis on service utilization. They 
stratified the same set of patients into only 3 CDR categories and used HUI scores to measure utility. This 
approach gives less information but it is more comparable to the ScHARR results. Patients utility scores were 
in mild, moderate and severe categories: 0.70, 0.53, 0.34 respectively.  These scores seem to highly correspond 
to both of Neumann’s previous analyses. 
Table 3. 3. 12. Patients HUI score by CDR severity level and service setting 
Disease severity Service setting HUI scores HUI scores average 
Mild AD Community AMCs 0.69 
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 MCOs 0.67 
Assisted 
Living 0.74 
 
Residential 
Nursing 
Home 0.71 
0.7 
AMCs 0.53 Community 
MCOs 0.56 
Assisted 
Living 0.56 
Moderate AD Residential 
Nursing 
Home 0.48 
0.53 
AMCs 0.36 Community 
MCOs 0.38 
Assisted 
Living 0.35 
Severe AD Residential 
Nursing 
Home 0.31 
0.34 
Source: Leon et al (2000) 
Relationship between literature’s findings and ScHARR analysis 
Comparing the results of the literature review with those set out in first part of this Appendix it can be seen that 
if we were to assume broadly that MMSE groups 0-10 related to severe, 11-20 related to moderate, and 21-30 
related to mild then the utility for clients in the mild, moderate and severe groups are within very similar 
ranges.   
For example 0.68-0.71 (Neumann et al 1998) or 0.67-0.74 (Leon et al 2000) for mild Alzheimer’s compares 
with a range of 0.72 up to 0.93 for MMSE groups 21-30, whilst 0.48-0.54 or 0.48-0.56 for moderate 
Alzheimer’s disease compares with a range of 0.40 to 0.71 for MMSE 11-20 and 0.31-0.37 or 0.31-0.38 for 
severe Alzheimer’s compares with a range of 0.29 to 0.38 for MMSE scores 4-10.   
Figure 3. 3. 3 Comparison of ScHARR results and US evidence on disease severity and utility 
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An important issue is that we could not consider any quality of life change following institutionalisation.  The 
other studies’ use of utility do separate QoL for institutionalised and community settings.  Therefore, our 
estimates are possibly conservative. 
5) Conclusions 
1. The Neumann et al. (1998, 1999) and Leon et al (2000) methodology for assessing quality of life in 
Alzheimer’s cases gives broadly similar results to our own analysis of the relationship between MMSE 
and utility.  
 
2. The Neumann et al. (1998, 1999) and Leon et al (2000)  methodology utilising the HUI 2 and the 
Torrance multi-attribute utility function is slightly different to our own methodology set out in the first 
part of this Appendix 
 
3. However  using a slightly different methodology and a different base data set still provides effectively 
the same results for quality of life weights for Alzheimer’s disease stages.   
 
4. The US results do not give any indication of invalidating our own analysis, indeed they support the 
broad conclusions. Therefore we can use for the calculation of utility in our cost effectiveness model the 
following equation derived from the regression in Table 3.3.9:  
Utility= 0.0982+MMSE*0.0298 
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